Çѱ¹°£´ãÃé¿Ü°úÇÐȸ Á¦13Â÷ ±¹Á¦½Ì±ÛÅäÇȽÉÆ÷Áö¿ò : 2018-09-14±³À°ÀÏÀÚ : 2018-09-14
±³À°Àå¼Ò : ¿©¼ö ¿¥ºíÈ£ÅÚ 1Ãþ ±×·£µåº¼·ë
±³À°ÁÖÁ¦ :
Á¦13Â÷ ±¹Á¦½Ì±ÛÅäÇȽÉÆ÷Áö¿ò ÁÖÃÖ±â°ü : Çѱ¹°£´ãÃé¿Ü°úÇÐȸ
´ã´çÀÚ : À̺¸¹Ì
¿¬¶ôó : 02-2227-8299
À̸ÞÀÏ :
khbps@khbp.or.kr ±³À°Á¾·ù : ¿Ü°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
Àü¶ó³²µµ±³À°½Ã°£ : 4 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í [Æò»ýȸ¿ø,Á¤È¸¿ø] »çÀüµî·Ï: 50,000¿ø / ÇöÀåµî·Ï 70,000¿ø [Àü°øÀÇ, °£È£»ç, ±ºÀÇ°ü] »çÀüµî·Ï: 30,000¿ø / ÇöÀåµî·Ï 50,000¿ø [ºñȸ¿ø] »çÀüµî·Ï: 70,000¿ø / ÇöÀåµî·Ï: 100,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 12:40~12:50 Introduction: Posthepatectomy Liver Failure (PHLF) ¹Ú»óÀç(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 12:50~13:10 Various factors associated with liver regeneration after hepatectomy ±è¼¼ÁØ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 13:10~13:30 Quantified risk assessment of PHLF in cirrhotic liver Á¤µ¿È¯(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 13:30~13:50 Impact and prediction of chemotherapy-associated liver injury ÇÑ´ëÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 13:50~14:10 Risk prediction of PHLF in patients with perihilar cholangiocarcinoma ÃÖ»õº°(°í·ÁÀÇ´ë)
Åä·Ð 09¿ù 14ÀÏ ±×·£µåº¼·ë 14:10~14:20 Discussion ()
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 14:20~14:50 Virtual and augmented reality for image-guided surgery Maki Sugimoto(International University of Health and Welfare)
ÈÞ½Ä 09¿ù 14ÀÏ ±×·£µåº¼·ë 14:50~15:10 Coffee Break ()
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 15:10~15:30 Knack and pitfall of various PVE techniques °í±â¿µ(¿ï»êÀÇ´ë ¿µ»óÀÇÇаú)
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 15:30~15:50 Outcome and safety of PVE between cirrhotic, cholestatic, and normal liver ¾È±Ù¼ö(°è¸íÀÇ´ë)
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 15:50~16:05 What next when PVE fails to induce enough hypertrophy? ÀÓâ¼·(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 16:05~16:20 Drawback of PVE: oncologic perspectives ÃÖ¿µ·Ï(ºÐ´ç¼¿ï´ë)
Åä·Ð 09¿ù 14ÀÏ ±×·£µåº¼·ë 16:20~16:30 Discussion ()
ÈÞ½Ä 09¿ù 14ÀÏ ±×·£µåº¼·ë 16:30~16:40 Break ()
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 16:40~16:55 Indication of PBD with regard to background liver, FLR and patient¡¯s condition ±èÈñÁØ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 16:55~17:10 Optimal preoperative bilirubin level with regard to background liver, FLR and patient¡¯s condition ¼ÇüÀÏ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 17:10~17:25 Endoscopic biliary drainage: is it oncologically safe? ±è¿ëÈÆ(°è¸íÀÇ´ë)
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 17:25~17:40 Simultaneous PVE and PBD; is it feasible? È«ÅÂÈ£(°¡Å縯ÀÇ´ë)
Åä·Ð 09¿ù 14ÀÏ ±×·£µåº¼·ë 17:40~17:50 Discussion ()